Alloimmunity & Trauma

Team Pham 21 December, 2018

Contents

Descriptive Statistics	1
Main results	1
Supplemental Figure 1: Antibody Frequency by Gender	-
Supplemental Figure 2: Antibody Frequency by Race	-

Descriptive Statistics

Main results

Total number of admission associated with AB is 47.

Supplemental Figure 1: Antibody Frequency by Gender

Supplemental Figure 2: Antibody Frequency by Race

Table 1: Clinical and Demographic Characteristics of Study Population

	Anti- (n = 4098)	Anti+ (n = 84)	p^a
age (mean (sd))	47.34 (19.11)	46.48 (20.31)	0.683
gender = M (%)	2918 (71.2)	57 (67.9)	0.583
race = Other (%)	2885 (70.4)	58 (69.0)	0.882
death = 1 (%)	463 (11.3)	19(22.6)	0.002
los (median [IQR])	11.61 [5.98, 22.29]	37.36 [24.17, 58.97]	< 0.001
RBCtrans (median [IQR])	1.00 [0.00, 5.00]	13.00 [6.00, 28.25]	< 0.001
plasmatrans (median [IQR])	0.00 [0.00, 1.00]	4.00 [0.00, 18.00]	< 0.001
cryop (median [IQR])	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	< 0.001
pp (median [IQR])	0.00 [0.00, 0.00]	1.00 [0.00, 4.00]	< 0.001
ntest (median [IQR])	2.00 [1.00, 3.00]	7.00 [4.00, 14.00]	< 0.001

Table 2: Antibody Characteristics: Antibody Specificity

Antibody	Pre Admission	Post Admission
c	1	0
\mathbf{C}	4	2
Cw	1	0
D	4	7
e	1	0
E	16	15
Fya	1	1
Jka	1	6
Jkb	2	0
K	9	0
Lea	1	4
Leb	1	1
M	9	3
NSE	12	28
S	1	1
V	1	0
A1	0	1

Table 3: Transfusion and Antibody Development

Number of RBC transfusion	Anti-	Anti+	% Developed Antibody During Encounter
0	1789	2	0.1116695
1-5	1439	17	1.1675824
6-10	503	18	3.4548944
11-20	263	19	6.7375887
>20	104	28	21.2121212

Table 4: Transfusion to Antibody Development Time

transToAnti1	transToAnti2	Ant1Ant2
Min.: 0.0083	Min.: 0.009	Min. : 0.000
1st Qu.: 0.3677	1st Qu.: 3.245	1st Qu.: 0.000
Median: 2.0000	Median: 5.620	Median: 3.049
Mean: 11.0608	Mean: 14.252	Mean: 3.191
3rd Qu.: 5.5087	3rd Qu.: 9.162	3rd Qu.: 4.234
Max. $:562.9458$	Max. $:562.946$	Max. :21.296